Get started
Author

Liz Darlison

Observed names: Darlison, L, Darlison, L., Darlison, Liz, L Darlison, L. DARLISON, L. Darlison
Observed institutions: National Health Service, University of Leicester, Glenfield Hospital, University Hospitals of Leicester NHS Trust, MRC Clinical Trials Unit at UCL, Papworth Hospital NHS Foundation Trust, De Montfort University
ORCID: 0000-0003-0157-1860
Observed ORCID: 0000-0003-0157-1860
OpenAlex ID: A5087272823
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
2011 · Tom Treasure, Loic Lang-Lazdunski, et al. · The Lancet Oncology · 708
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
2008 · Martin F Muers, Richard J Stephens, et al. · The Lancet · 260
PDF
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
2021 · Dean A Fennell, Sean Ewings, et al. · The Lancet Oncology · 256
PDF
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
2018 · Ian Woolhouse, Lesley Bishop, et al. · Thorax · 220
PDF
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
2021 · Dean A Fennell, Amy King, et al. · The Lancet Respiratory Medicine · 112
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma
2020 · Eric Lim, Liz Darlison, et al. · BMJ Open · 80
PDF
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
2022 · Dean A Fennell, Amy King, et al. · The Lancet Oncology · 79
Living with mesothelioma. A literature review
2009 · S. MOORE, L. DARLISON, et al. · European Journal of Cancer Care · 79
PDF
Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
2019 · Neil Bayman, Wiebke Appel, et al. · Journal of Clinical Oncology · 65
BTS guideline for the investigation and management of malignant pleural mesothelioma
2018 · Ian Woolhouse, Lesley Bishop, et al. · BMJ Open Respiratory Research · 39
PDF
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
2021 · Dean Anthony Fennell, Angela Claire Casbard, et al. · Journal of Clinical Oncology · 35
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
2021 · D. Fennell, C. Ottensmeier, et al. · Journal of Thoracic Oncology · 34
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
2024 · Min Zhang, Aleksandra Bzura, et al. · Nature Communications · 33
PDF
Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention
2016 · N Bayman, D Ardron, et al. · BMJ Open · 30
PDF
Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review
2021 · Madeleine Harrison, Clare Gardiner, et al. · Palliative Medicine · 27
PDF
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
2022 · Dean A. Fennell, Catharine Porter, et al. · EClinicalMedicine · 26
PDF
Leveraging the pleural space for anticancer therapies in pleural mesothelioma
2024 · Kevin G Blyth, Prasad S Adusumilli, et al. · The Lancet Respiratory Medicine · 17
A multicentre non-blinded randomised controlled trial to assess the impact of regular early specialist symptom control treatment on quality of life in malignant mesothelioma (RESPECT-MESO): study protocol for a randomised controlled trial
2014 · Samal Gunatilake, Fraser JH Brims, et al. · Trials · 15
PDF
Gender and the experiences of living with mesothelioma: A thematic analysis
2021 · Stephanie Ejegi-Memeh, Steve Robertson, et al. · European Journal of Oncology Nursing · 11
PDF
A systematic review of the barriers and facilitators impacting patient enrolment in clinical trials for lung cancer
2024 · Benjamin Lond, Christopher Dodd, et al. · European Journal of Oncology Nursing · 10
PDF
An analysis of lung cancer clinical nurse specialist workload and value
2008 · Alison Leary, Macmillan, et al. · Cancer Nursing Practice · 10
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
2025 · Dean A. Fennell, Kayleigh Hill, et al. · Nature Communications · 9
PDF
Understanding the Experiences of end of Life Care for Patients with Mesothelioma from the Perspective of Bereaved Family Caregivers in the UK: A Qualitative Analysis
2022 · Madeleine Harrison, Liz Darlison, et al. · Journal of Palliative Care · 9
PDF
Findings from the National Mesothelioma Experience Survey
2014 · Liz Darlison, Dawn Mckinley, et al. · Cancer Nursing Practice · 9
The experience of living with mesothelioma: A meta-ethnographic review and synthesis of the qualitative literature.
2022 · Benjamin Lond, Kerry Quincey, et al. · Health Psychology · 8
Works count: 121
Citation count: 2,377
H-index: 17
I10-index: 22
Year
Topic
Type